🔵 14 June marks the start of Familial Adenomatous Polyposis #FAP Awareness Week! 🎙️ Megan Dwyer, MS, CGC, a CGA-IGC Communications Committee member, speaks w/ Michael Caprio, author & patient advocate, about his personal FAP journey. 💻 Watch or listen to the full discussion here 👉 🔗youtu.be/z8Dy_Pt0GJs Throughout the week, we’ll share key highlights, including: 🧬 FAP diagnosis can feel overwhelming 💙 Emotional support matters 🏥 Surgery has medical psychosocial impacts 🔎 Long-term surveillance is essential 👨‍👩‍👧 Family planning may evolve 🤝 Peer support can help 📍Stay tuned! #FAPAwarenessWeek #HereditaryGICancer #GeneticCounseling #PatientAdvocacy

📣 Ready to help shape the future of hereditary GI cancer care and research? CGA-IGC is inviting self-nominations from current members for its Working Committees and Executive Council. 🌟 🚨This is a meaningful opportunity to contribute your expertise, connect with colleagues across disciplines, and help advance the work of the premier professional scientific society dedicated to hereditary gastrointestinal cancers. 🧬 ➡️ Learn more about our Working Committees: cgaigc.com/cga-committees ➡️ Submit your self-nomination: surveymonkey.com/r/2026CGAIG… All nominees must be current 2026 CGA-IGC members in good standing and maintain membership throughout the proposed term. ✅ Not yet a member or need to renew? Now is the perfect time to join if you would like to self-nominate for a committee or leadership position. Visit cgaigc.com to learn more. #HereditaryGICancer #GeneticCounseling #Gastroenterology #Oncology #CancerResearch @josiebakerGC

Not so insignificant after all: VUS impacted clinician decisions in 92% of studies vs 56% for patient decisions. And some patients terminated pregnancies based on VUS alone. bit.ly/4oEKVEd

🧬 Curious about the Lynch syndrome vaccine space? CGA-IGC Communications Committee member Blake Jones, MD, shares insights on a recent Familial Cancer article summarizing LS vaccine trials and dendritic cell-based prevention strategies. 📖 Read it here: 🔗cgaigc.com/post/updates-in-v… 🚨 Also exciting: FDA Fast Track Designation was granted to Nouscom's NOUS-209 for Lynch syndrome cancer prevention. 💡 Momentum is building around prevention and interception strategies for #LynchSyndrome 🔗 Full article: trial.medpath.com/news/fda-g… #HereditaryGICancer

#Universal #germline #genetictesting found PGVs in 15% of #patients w/ #neuroendocrine #neoplasms (NENs) inc. #pancreas & #smallbowel NENs 35% of PGV-positive #patients did not meet @NCCN criteria c/w jamanetwork.com/journals/jam… @J_Samadder et al. @JAMAOnc ascopubs.org/doi/10.1200/JCO… @VivekSubbiah @Dr_R_Kurzrock @JCO_ASCO @ASCO ...the value of [#genetictesting] in #NET #patients, identifying...#treatment options More evidence for #Universal #germlinetesting in all #patients w/ #cancer #access #reducedisparities #precisionmedicine #precisiontherapy #clinicaltrials #precisionprevention @CGAIGC @PanCAN journals.lww.com/pancreasjou… #OluseyiAbidoye et al. @MayoClinic #Pancreas @Wolters_Kluwer

Universal genomics needed. We can’t keep missing the diagnosis. We have clinic embedded excellent genetic counsellor— Phebe Lemert—in our Precision Oncology and Rare Cancers Clinic/Center ascopubs.org/doi/10.1200/OA-… 🔥🎯➡️

50% of #patients [w/ #cancer] positive for #germline variants did not meet @NCCN testing criteria, in a #PrecisionMedicine clinic providing #universal #germlinetesting to all #patients w/ common & rare #cancers 15% of all #patients had #pathogenic #germline #variants (PGVs) 13% of #patients w/ common #cancers (inc #breastcancer #lungcancer #CRC #pancreaticcancer #prostatecancer) 17% of #patients w/ rare #cancers (inc #sarcoma #braincancer #cholangiocarcinoma) c/w jamanetwork.com/journals/jam… #PiperNicolosi et al. @JAMAOnc ascopubs.org/doi/full/10.120… @beitsch et al. @JCO_ASCO ascopubs.org/doi/full/10.120… #NealShore et al. @JCOOP_ASCO jamanetwork.com/journals/jam… @WhitworthMD et al. @JAMANetworkOpen jamanetwork.com/journals/jam… @J_Samadder et al. @JAMAOnc mdpi.com/1422-0067/26/7/2839 #IsaacAilts et al. @MDPIOpenAccess ascopubs.org/doi/10.1200/JCO… @VivekSubbiah @Dr_R_Kurzrock @JCO_ASCO Overall, our data support #universal [#pancancer] #germlinetesting as a strategy to uncover clinically valuable information...including...#medical management, #targeted #treatment... #access #reducedisparities #genetictesting #precisionmedicine #precisiontherapy #clinicaltrials #precisionprevention ascopubs.org/doi/pdf/10.1200… #PhebeLemert @Dr_R_Kurzrock et al. @MedicalCollege @JCOOA_ASCO @ASCO

This is clinically meaningful ! @OncoAlert

SERENA-6: Very robust data with updated PFS, significant PFS2, and impressive ctDNA clearance. @OncoAlert #ASCO26

📣 New CGA-IGC research webinar series! ➡️Developed by the Research Committee, this 3-part series explores the “research story” behind real hereditary GI cancer projects - from research gap to study design, IRB, funding & lessons learned. 📍We’re kicking off the series with Webinar 1, featuring Timothy Yen, MD (@TimYen1), gastroenterologist at Loma Linda University and CGA-IGC Research Committee member. 🖥️ Familial Colorectal Cancer Risk Among Those with Advanced Colorectal Polyps 🗓️ July 1, 2026 | 5 PM ET / 2 PM PT 💡 Learn how an everyday administrative burden became a meaningful QI opportunity. ✅ Register here : 🔗addevent.com/event/kqljmb35g… @josiebakerGC

Great to connect with @AllisonKurian #StevenKatz #LeeGibbs @ASCO! "Correlates of patient enrollment in population-based randomized controlled trial of cascade genetic testing in families with hereditary cancer susceptibility", asco.org/abstracts-presentat… #ASCO26 @Stanford @UMich

⭐️⭐️⭐️Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer | New England Journal of Medicine @NEJM nejm.org/doi/full/10.1056/NE…

9.3% of #Chinese #patients w/ #colorectalcancer had #pathogenic #germline #variants (PGVs) w/ #genetictesting...50% of #patients w/ PGVs had no family history, 29% dx'ed >65yo, highlighting the limitations of @NCCN criteria. #CRC #Patients w/ #germline PGVs demonstrated significantly better #PFS Our findings challenge current [@NCCN] #genetictesting guidelines...suggest that the existing criteria may miss a substantial proportion of [#patients w/ PGVs]...& support broader #genetictesting c/w sciencedirect.com/science/ar… @PedroUson @AGA_CGH ascopubs.org/doi/10.1200/JCO… @VivekSubbiah @Dr_R_Kurzrock @JCO_ASCO @ASCO #Universal #germlinetesting for all #patients w/ #CRC #acces #reducedisparities #precisionmedicine #precisiontherapy #clinicaltrials #precisionprevention @CGAIGC @FightCRC onlinelibrary.wiley.com/doi/… #LitingLu et al. #CancerMedicine @wileyinresearch

⭐️Delighted to share the final analysis of ARROW trail with pralsetinib in RET‑altered thyroid cancers @ASCO #ASCO26 I’ll never forget the very first ever RET patient in the universe that we enrolled 👉🏼That moment it was clear this drug had real potential to get to finish line. Years later, it’s incredibly rewarding to see it become another option for RET patients @RetRenegades @RETpositive @oncodaily @OncoAlert @OpenMedicineHQ

Wow! 🤩 Practice Changing @NEJM RAS inhibition in Pancreatic Cancer! #precisonmedicine for the win @OncoAlert nejm.org/doi/full/10.1056/NE…

Cheers, chills, and a standing ovation when RASolute 302 showed unprecedented survival on daraxonrasib for patients with progressive pancreatic cancer Seldom do you sense you’re witnessing a historic moment in cancer care but this feels like ras targeting has arrived #ASCO26

📢 In case you missed it: an important milestone for Lynch syndrome care and advocacy, a dedicated ICD-10 code for Lynch syndrome. This progress reflects the impact of advocacy led by @FightCRC with support from CGA-IGC members and other partners. ➡️In this video, Dr. Peter Stanich explains why this change matters for patients, families, clinicians, and health systems🩺 #LynchSyndrome #HereditaryCancer #HereditaryGICancer #GeneticTesting #CancerPrevention @asaf_maoz @EdEsplin @MSpringerGC @HHampel1 @josiebakerGC @pAla2Arg

...multi-gene panels (#germlinetesting) have emerged as the standard of care for inherited #cardiac conditions (e.g. #cardiomyopathies, etc.)...contributing to...#prognostic assessment, & personalized #therapeutic decision-making... cit. 'Comprehensive #GeneticTesting for #Pediatric #HypertrophicCardiomyopathy' link.springer.com/article/10… #DrDanaGal et al. @Stanford @SpringerNature #Universal #germline #genetictesting for all #patients w/ #cardiomyopathy #access #reducedisparities #precisionmedicine #precisiontherapy #clinicaltrials #precisionprevention mdpi.com/2075-1729/16/5/796 #KonstantinosAgiannitopoulos et al. @Life_MDPI @MDPIOpenAccess

10.7% of #patients w/ #mucosalmelanoma/#MM had pathogenic germline variants (#PGVs) on #germline #genetictesting in genes inc. #CHEK2, #ATM, #MITF, #BRCA2, #TP53. ...the 10.7% prevalence of PGVs exceeds the commonly cited 5% threshold frequently used to justify #clinical #genetictesting ...our study provides a strong rationale for incorporation of #germlinetesting into the care of #patients w/ #MM. c/w sciencedirect.com/science/ar… @FunchainMD et al. @Stanford & jaad.org/article/S0190-9622(… #DrCollinCostello et al. @MayoClinic @JAADjournals #Universal #germlinetesting for all #patients w/ #melanoma #access #reducedisparities #precisionmedicine #precisiontherapy #clinicaltrials #precisionprevention nature.com/articles/s41525-0… #AfsanehAmouzegar et al. @UTMDAnderson @Nature_NPJ

📣 Join us for the third webinar of our 2026 webinar series titled, “Gastric Pathology and Surgical Perspectives.” 📅 Date: Monday, June 15 🕛 Time: 12:00 PM ET / 9:00 AM PT 🔗 Register 👉 cgaigc.com/webinars 🚨Join the CGA-IGC for an engaging, multidisciplinary webinar on the management of CDH1 🧬, featuring complementary perspectives from pathology 🔬 and surgical oncology 🏥. ➡️ Dr. Namrata Setia will highlight key gastrointestinal pathology considerations essential for accurate diagnosis and risk assessment, while Dr. Paul Mansfield will discuss clinical decision-making, including surveillance strategies and surgical management. 📍 This session will provide a comprehensive, practical overview to guide clinicians navigating the complexities of CDH1-associated cancer risk. #HereditaryGICancer @josiebakerGC @GCJulieMosk